Ingrid Choong
Plus aucun poste en cours
Fortune : 3 396 $ au 30/04/2024
Historique de carrière de Ingrid Choong
Anciens postes connus de Ingrid Choong
Sociétés | Poste | Début | Fin |
---|---|---|---|
EIGER BIOPHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - | 01/09/2023 |
Investor Relations Contact | 01/01/2008 | - | |
Public Communications Contact | 01/01/2008 | - | |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Investor Relations Contact | - | 29/03/2016 |
Corporate Officer/Principal | 11/08/2011 | - | |
VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/1999 | 01/01/2008 |
Formation de Ingrid Choong
California Institute of Technology | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Investor Relations Contact | 2 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Ingrid Choong
- Expérience